New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model

Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin B cell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed, cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partial remission of disease in less than half percent of PEL patients. Bortezomib (BZ) is a proteasome inhibitor mainly used for the treatment of Multiple Myeloma (MM). Here we investigated if Chloroquine supplementation could potentiate the outcome of BZ treatment in vivo, in NSG mouse model.